Jakafi (ruxolitinib) — Medica

Initial criteria

• age ≥ 18 years
• patient has peripheral T-cell lymphoma OR (patient has T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, hepatosplenic T-cell lymphoma, or breast implant-associated anaplastic large cell lymphoma AND has tried at least one systemic regimen)

Approval duration

1 year